Podcast
0.25 CME/CE Credit
Sarcoidosis in the Lungs: What Primary Care Providers Should Know
“Sarcoidosis in the Lungs: What Primary Care Providers Should Know” is a CME podcast episode produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode, we are joined by Dr. George Mensah, Director of the NHLBI Center for Translation Research and Implementation Science, and Dr. Mridu Gulati, Associate Professor of Medicine at Yale School of Medicine. We will be discussing what general practitioners should know about sarcoidosis, including the risk factors, symptoms, challenges in diagnosis, and how sarcoidosis is treated.
Already listened on another platform?
CME/CE Information
0.25 AMA PRA Category 1 Credits™, 0.25 ABIM MOC or 0.25 AANP, including 0.25 AANP Pharm
Release Date: 9/5/2023
Expiration Date: 5/31/2025
Topics
Learning Objectives
- Identify individuals at risk for sarcoidosis
- Recognize the signs and symptoms of sarcoidosis and its complications
- Describe the primary care provider’s role in diagnosing sarcoidosis
- Discuss the pharmacologic agents used for treating sarcoidosis
Faculty
George A. Mensah, MD, FACC, FAHA
Director
NHLBI Center for Translation Research and Implementation Science
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Mridu Gulati, MD, MPH: Speaker for Boehringer Ingelheim. Advisor for CDC/NIOSH. Researcher for Boehringer Ingelheim and Bristol Myers Squibb.
George A. Mensah, MD: No relevant financial relationships disclosed.
Charles Vega, MD, FAAFP (Moderator): Consultant for GlaxoSmithKline.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and the National Heart, Lung, and Blood Institute of the National Institutes of Health. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
Designation Statement
This activity is approved for 0.25 contact hour of continuing education, which includes 0.25 hour of pharmacology.
Supporters and Partners
Education Partner
Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.